Back

Dapagliflozin in primary prevention of cardiotoxicity induced by anthracycline-trastuzumab therapy through activation of pAMPK and inhibition of MyD88 and NLRP-3

20 June 2025 (00:00 - 00:00)
Organised by: Logo
Congress Presentation Part of: Insights into anthracycline-induced cardiotoxicity and treatment perspectives Cardio-Oncology CCO Premium Access ESC Cardio-Oncology 2025 Council of Cardio-Oncology

About the speaker

Photo
Doctor Vincenzo Quagliariello

National Cancer Institute G.Pascale Foundation IRCCS, Naples (Italy)

9 More presentations in this session

Presentation thumbnail
Targeted cardiac inactivation of Guanylate binding protein 5 (GBP5) protects from cardiotoxicity after doxorubicin treatment
Associate Professor L. Lehmann (Heidelberg, DE)
Abstract Slides
Presentation thumbnail
Cardiac troponin autoantibodies in breast cancer patients receiving adjuvant cardiotoxic chemotherapy: the PRADA study
Ms H. Junes (Turku, FI)
Abstract Slides
Presentation thumbnail
Cardioprotective effects of the flavonoid quercetin against doxorubicin-Induced cardiotoxicity in H9c2 cardiomyoblasts
Doctor N. Chong (Nottingham, GB)
Abstract Slides
Presentation thumbnail
Exploring the cardioprotective efficacy of roflumilast as potential cAMP regulator against experimental epirubicin-induced myocardial injury: insights into oxidative stress and apoptosis.
Slides
Presentation thumbnail
Anthracycline exposure alters the response to future cardiac stress response driven by FOXK1
Mr V. Sunder (Heidelberg, DE)
Abstract Slides

Access the full session

Session thumbnail
Insights into anthracycline-induced cardiotoxicity and treatment perspectives

The Event

Event poster

ESC Cardio-Oncology 2025

20 June - 21 June 2025

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources